Abstract
BackgroundBiologicals possess a large variation in pharmacokinetics (1). Subtherapeutic drug levels and formation of anti-drug antibodies (ADAb) decrease their efficacy in rheumatoid arthritis (RA) patients (2). Measuring these can become...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
